Donor-reactive HLA antibodies in renal allograft recipients: Considerations, complications, and conundrums

Human Immunology

Volumn 70, Issue 8, 2009, Pages 610-617

  Gebel, Howard M ^a   Moussa, Omar ^b   Eckels, David D ^c   Bray, Robert A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Donor directed antibodies; HLA alleles; HLA antibodies; HLA antigens; Solid phase assays

Indexed keywords

ALEMTUZUMAB; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; DESENSITIZATION; DONOR SELECTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; FLOW CYTOMETRY; GLOMERULOPATHY; GRAFT RECIPIENT; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNE SYSTEM; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; PLASMAPHERESIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK FACTOR; SEQUENCE ANALYSIS;

ANTIBODY FORMATION; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION CONDITIONING;

EID: 68049120205     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.04.012     Document Type: Article

References (59)

1. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
2. Braun W.E. Laboratory and clinical management of the highly sensitized organ transplant recipient. Hum Immunol 26 (1989) 245-260
3. Gebel H.M., Bray R.A., and Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 3 (2003) 1488-1500
4. Amos D.B., Bashir H., Boyle W., MacQueen M., and Tiilikainen A. A simple micro cytotoxicity test. Transplantation 7 (1969) 220-223
5. Cross D.E., Whittier F.C., Weaver P., and Foxworth J. A comparison of the antiglobulin versus extended incubation time crossmatch: Results in 223 renal transplants. Transplant Proc 9 (1977) 1803-1806
6. Fuller T.C., Cosimi A.B., and Russell P.S. Use of an antiglobulin-ATG reagent for detection of low levels of alloantibody-improvement of allograft survival in presensitized recipients. Transplant Proc 10 (1978) 463-466
7. Johnson A.H., Rossen R.D., and Butler W.T. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: Identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens 2 (1972) 215-226
8. Iwaki Y., Lau M., Cook D.J., Takemoto S., and Terasaki P.I. Crossmatching with B and T cells and flow cytometry. Clin Transpl (1986) 277-284
9. Christiaans M.H., Overhof R., ten Haaft A., Nieman F., van Hooff J.P., and van den Berg-Loonen E.M. No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically well-documented renal allograft recipients. Transplantation 62 (1996) 1341
10. Gebel H.M., and Bray R.A. Laboratory assessment of HLA antibodies circa 2006: Making sense of sensitivity. Transplantation Reviews 20 (2006) 189-194
11. Kao K.J., Scornik J.C., and Small S.J. Enzyme-linked immunoassay for anti-HLA antibodies-an alternative to panel studies by lymphocytotoxicity. Transplantation 55 (1993) 192-196
12. Pei R., Wang G., Tarsitani C., Rojo S., Chen T., Takemura S., et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 59 (1998) 313-322
13. Kerman R.H., Susskind B., Buyse I., Pryzbylowski P., Ruth J., and Warnell S. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 68 (1999) 1855-1858
14. Bray R.A., Nickerson P.W., Kerman R.H., and Gebel H.M. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 29 (2004) 41-54
15. Lefaucheur C., Suberbielle-Boissel C., Hill G.S., Nochy D., Andrade J., and Antoine C. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 8 (2008) 324-331
16. Reinsmoen N.L., Lai C.H., Vo A., Cao K., Ong G., Naim M., Wang Q., and Jordan S.C. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86 (2008) 820-825
17. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 85 (2008) 1046-1050
18. van den Berg-Loonen E.M., Billen E.V., Voorter C.E., van Heurn L.W., Claas F.H., van Hooff J.P., and Christiaans M.H. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 85 (2008) 1086-1090
19. Bohmig G.A., Bartel G., and Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 13 (2008) 411-418
20. Cai J., and Terasaki P.I. Humoral theory of transplantation: Mechanism, prevention, and treatment. Hum Immunol 66 (2005) 334-342
21. Saw C.L., Bray R.A., and Gebel H.M. Cytotoxicity and antibody binding by flow cytometry: A single assay to simultaneously assess two parameters. Cytometry B Clin Cytom 74 (2008) 287-294
22. Bielmann D., Honger G., Lutz D., Mihatsch M.J., Steiger J., and Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 7 (2007) 626-632
23. Patel A.M., Pancoska C., Mulgaonkar S., and Weng F.L. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 7 10 (2007) 2371-2377
24. Zachary A.A., Montgomery R.A., and Leffell M.S. Defining unacceptable HLA antigens. Curr Opin Organ Transplant 13 (2008) 405-410
25. Eng H.S., Bennett G., Tsiopelas E., Lake M., Humphreys I., Chang S.H., Coates P.T., and Russ G.R. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 8 (2008) 2335-2342
26. Issa N., Cosio F.G., Gloor J.M., Sethi S., Dean P.G., Moore S.B., DeGoey S., and Stegall M.D. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 86 (2008) 681-685
27. Appel III J.Z., Hartwig M.G., Cantu III E., Palmer S.M., Reinsmoen N.L., and Davis R.D. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 81 (2006) 1049-1057
28. Bray R.A., Nolen J.D., Larsen C., Pearson T., Newell K.A., Kokko K., Guasch A., et al. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 6 (2006) 2307-2315
29. Zangwill S., Ellis T., Stendahl G., Zahn A., Berger S., and Tweddell J. Practical application of the virtual crossmatch. Pediatr Transplant 11 (2007) 650-654
30. Jordan S.C., Vo A., Bunnapradist S., Toyoda M., Peng A., Puliyanda D., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76 (2003) 631-636
31. Montgomery R.A., Zachary A.A., Racusen L.C., Leffell M.S., King K.E., Burdick J., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70 (2000) 887-895
32. Gloor J., Cosio F., Lager D.J., and Stegall M.D. The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 8 (2008) 1367-1373
33. Haririan A., Nogueira J., Kukuruga D., Schweitzer E., Hess J., and Gurk-Turner C. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 3 (2009) 536-542
34. West-Thielke P., Herren H., Thielke J., Oberholzer J., Sankary H., Raofi V., et al. Results of positive cross-match transplantation in African American renal transplant recipients. Am J Transplant 8 (2008) 348-354
35. Stegall M, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant (in press).
36. Mulder A., Eijsink C., Kardol M.J., Franke-van Dijk M.E., van der Burg S.H., Kester M., et al. Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC class I tetramers. J Immunol 171 (2003) 6599-6603
37. Perry D.K., Pollinger H.S., Burns J.M., Rea D., Ramos E., Platt J.L., Gloor J.M., and Stegall M.D. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 8 (2008) 133-143
38. Hanto R.L., Reitsma W., and Delmonico F.L. The development of a successful multiregional kidney paired donation program. Transplantation 86 (2008) 1744-1748
39. Iwaki Y., Cook D.J., Terasaki P.I., Lau M., Terashita G.Y., Danovitch G., et al. Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc 19 (1987) 764-766
40. Mahoney R.J., Ault K.A., Given S.R., Adams R.J., Breggia A.C., Paris P.A., et al. The flow cytometric crossmatch and early renal transplant loss. Transplantation 49 (1990) 527-535
41. Ogura K., Terasaki P.I., Johnson C., Mendez R., Rosenthal J.T., Ettenger R., et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 56 (1993) 294-298
42. Pelletier R.P., Orosz C.G., Adams P.W., Bumgardner G.L., Davies E.A., Elkhammas E.A., et al. Clinical and economic impact of flow cytometry crossmatching in primary cadaveric kidney and simultaneous pancreas-kidney transplant recipients. Transplantation 63 (1997) 1639-1645
43. Ettenger R.B., Jordan S.C., and Fine R.N. Cadaver renal transplant outcome in recipients with autolymphocytotoxic antibodies. Transplantation 35 (1982) 429-431
44. Vaidya S., Cooper T.Y., Avandsalehi J., Barnes T., Brooks K., Hymel P., et al. Improved flow cytometric detection of HLA alloantibodies using pronase: Potential implications in renal transplantation. Transplantation 71 (2001) 422-428
45. Karuppan S.S., Ohlman S., and Moller E. The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation 54 (1992) 839-844
46. Bray R.A., and Grebel H.M. Allele specific HLA alloantibodies: Implication for organ allocation. Am J Transplant 5 s11 (2005) p 488
47. Gloor J.M., DeGoey S., Ploeger N., Gebel H., Bray R., Moore S.B., et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 78 (2004) 221-227
48. Jordan S.C., Vo A.A., Peng A., Toyoda M., and Tyan D. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6 (2006) 459-466
49. Watanabe J., and Scornik J.C. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 5 (2005) 2786-2790
50. Gloor J.M., Cosio F.G., Rea D.J., Wadei H.M., Winters J.L., Moore S.B., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6 (2006) 1841-1847
51. Haas M., Rahman M.H., Racusen L.C., Kraus E.S., Bagnasco S.M., Segev D.L., et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 6 (2006) 1829-1840
52. Stegall M.D., Gloor J., Winters J.L., Moore S.B., and Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 (2006) 346-351
53. Akalin E., Ames S., Sehgal V., Fotino M., Daly L., Murphy B., and Bromberg J.S. Intravenous immunoglobulin and Thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 76 (2003) 1444-1447
54. Rebellato L.M., Gross U., Verbanac K.M., and Thomas J.M. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 57 (1994) 685-694
55. Gebel H.M., Bunce M., Crosby I., Nolan J.D.L., and Bray R.A. Masking of HLA antibodies by Thymoglobulin. Hum Immunol 66 Suppl 1 (2005) S12
56. Bearden C.M., Book B.K., Sidner R.A., and Pescovitz M.D. Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing. J Immunol Methods 300 (2005) 192-199
57. Vieira C.A., Agarwal A., Book B.K., Sidner R.A., Bearden C.M., Gebel H.M., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 (2004) 542-548
58. Bearden C.M., Agarwal A., Book B.K., Sidner R.A., Gebel H.M., Bray R.A., and Pescovitz M.D. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 65 (2004) 803-809
59. Book B.K., Agarwal A., Milgrom A.B., Bearden C.M., Sidner R.A., Higgins N.G., and Pescovitz M.D. New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc 37 (2005) 640-642